Optimizing the lung cancer screening interval: The world is waiting

Journal of Thoracic Disease

Volumn 8, Issue 10, 2016, Pages E1369-E1370

  Ridge, Carole A ^a   Boiselle, Phillip M ^b  

^a MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC VALUE; EMPHYSEMA; FEASIBILITY STUDY; HUMAN; LUNG CANCER; LUNG NODULE; MORTALITY RATE; NOTE; PREDICTIVE VALUE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SCREENING TEST; THORAX RADIOGRAPHY;

EID: 84995484429     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.21037/jtd.2016.10.25     Document Type: Note

References (5)

1. Aberle DR, DeMello S, Berg CD, et al. Results of the two incidence screenings in the National Lung Screening Trial. N Engl J Med 2013;369:920-31
2. Field JK, Duffy SW. Lung cancer CT screening: is annual screening necessary? Lancet Oncol 2016;17:543-4
3. Patz EF Jr, Greco E, Gatsonis C, et al. Lung cancer incidence and mortality in National Lung Screening Trial participants who underwent low-dose CT prevalence screening: a retrospective cohort analysis of a randomised, multicentre, diagnostic screening trial. Lancet Oncol 2016;17:590-9
4. Ruchalski KL, Brown K. Lung Cancer Screening Update. J Thorac Imaging 2016;31:190-200
5. Heuvelmans MA, Vliegenthart R, Oudkerk M. Contributions of the European trials (European randomized screening group) in computed tomography lung cancer screening. J Thorac Imaging 2015;30:101-7